口腔癌快速检测试剂盒市场（2026—2031）
口腔癌快速检测试剂盒市场预计由2026年的20.1亿美元增至2031年的25.8亿美元，预测期复合年增长率为5.12%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
口腔癌快速检测试剂盒市场预计由2026年的20.1亿美元增至2031年的25.8亿美元，预测期复合年增长率为5.12%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 5.12% | 机构预测 |
| 市场规模 | 2026 | USD 2.01 billion | 机构预测 |
| 市场规模 | 2031 | USD 2.58 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| detection_principle | Immunoassay Tests | 2025 | 41.240% |
| end_user | Hospitals and Clinics | 2025 | 45.840% |
| geography | North America | 2025 | 41.410% |
| sample_type | Saliva-Based Testing | 2025 | 46.240% |
| turnaround_time | the 15-60 Minutes category | 2025 | 47.140% |
关键结论
- detection_principle 维度中，Immunoassay Tests 在 2025 年的公开份额为 41.24%。
- end_user 维度中，Hospitals and Clinics 在 2025 年的公开份额为 45.84%。
- geography 维度中，North America 在 2025 年的公开份额为 41.41%。
- sample_type 维度中，Saliva-Based Testing 在 2025 年的公开份额为 46.24%。
- turnaround_time 维度中，the 15-60 Minutes category 在 2025 年的公开份额为 47.14%。
主要参与者
- Vigilant Biosciences
- Viome Life Sciences
- Abviris Deutschland GmbH
- ErlySign
- Supriya Lifescience Ltd.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Oral Cancer Incidence and High-Risk Exposure | +0.900% | Global, concentrated in South Asia, East Asia, and Sub-Saharan Africa | Long term (≥ 4 years) |
| Earlier Non-Invasive Detection Demand | +0.800% | North America and Europe, with adoption spillover to APAC | Medium term (2-4 years) |
| Decentralized Saliva Screening and Home Use | +0.800% | North America, Western Europe, early-stage uptake in APAC and MEA | Medium term (2-4 years) |
| Dental and Diagnostic Center Network Expansion | +0.700% | North America, EU, GCC, India | Short term (≤ 2 years) |
| Salivaomics and Multimarker Interpretation | +0.600% | North America, Japan, South Korea, Germany | Long term (≥ 4 years) |
| Portable Lab-on-Chip Adoption | +0.600% | Global, especially APAC and MEA in low-resource settings | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Limited Clinical Validation and Regulatory Uncertainty | -0.700% | Global, most acute in North America and EU | Long term (≥ 4 years) |
| Nonuniform Screening and Reimbursement Pathways | -0.600% | North America, Western Europe, structural in APAC and MEA | Medium term (2-4 years) |
| Collection, Storage, and Biomarker Stability Variability | -0.400% | Global, most critical in home use and low-resource settings | Short term (≤ 2 years) |
| False-Positive Risk and Confirmatory Biopsy Dependence | -0.400% | North America and EU | Medium term (2-4 years) |
报告关注的关键问题
What is driving demand for oral cancer rapid test kits?
Earlier detection needs, saliva-based sampling, and screening expansion through dental and diagnostic channels are supporting adoption.
How large is the oral cancer rapid test kit market?
It is projected to grow from USD 2.01 billion in 2026 to USD 2.58 billion by 2031 at a 5.12% CAGR.
Which product type holds the largest position?
OncAlert Oral Cancer LAB held the leading product-type share at 35.31% in 2025.
Which testing method is growing fastest?
Sensor-Based Tests are projected to grow at a 7.42% CAGR through 2031.
Why is saliva used for oral cancer screening?
Saliva is noninvasive, can be self-collected, and contains several biomarkers associated with oral squamous cell carcinoma.
What is limiting the broader adoption of rapid kits?
Clinical validation requirements, inconsistent screening practices, reimbursement exclusions, and the need for confirmatory biopsy remain key constraints.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence